By the third quarter of 2026, 49 gene therapies had been approved worldwide and 4,594 gene, cell and RNA therapies were in development.
Why this market is moving now
- Sector financing rose 43% in the first three quarters of 2026 compared with the same period of 2025.
- Breyanzi sales rose 82% to $1,358 million in 2025.
- Itvisma, a new form of Zolgensma, lifted Zolgensma group sales 34% in the third quarter of 2026.
- The global pipeline reached 4,594 gene, cell and RNA therapies in the third quarter of 2026.
Key figures
Global figures for this market, with the year each one describes. Use Cite to copy a reference to this page.
| Figure | Value | Year | Cite |
|---|---|---|---|
| Global cell and gene therapy sales were $10.2 billion in 2025 and are forecast to reach $59.3 billion in 2031. | 10.2 USD billion | 2025 | |
| Cell and gene therapy companies worldwide raised more than $11.3 billion in the first three quarters of 2026, up 43% from the same period of 2025. | 11.3 USD billion (more than, January to September, preliminary) | 2026 | |
| As of the third quarter of 2026, 49 gene therapies, including genetically modified cell therapies, and 77 other cell therapies had been approved for clinical use worldwide. | 49 gene therapies approved (cumulative) | 2026 | |
| 4,594 gene, cell and RNA therapies were in development worldwide in the third quarter of 2026, from preclinical work to pre-registration. | 4,594 therapies in development | 2026 | |
| Carvykti net trade sales were about $1.9 billion in 2025, and more than 10,000 patients had been treated with it. | 1.9 USD billion (net trade sales) | 2025 | |
| Bristol Myers Squibb's Breyanzi sales were $1,358 million worldwide in 2025, up 82%. | 1,358 USD million | 2025 | |
| Sarepta recorded $898.7 million of Elevidys net product revenue in 2025. | 898.7 USD million | 2025 | |
| Novartis' Zolgensma group sales were $404 million in the third quarter of 2026, up 34%, helped by the launch of Itvisma, with more than 6,000 patients treated worldwide since launch. | 404 USD million (quarter) | 2026 | |
| Gilead's cell therapy sales, from Yescarta and Tecartus, fell 18% to $355 million in the third quarter of 2026. | 355 USD million (quarter) | 2026 | |
| Vertex recorded Casgevy revenue of $99 million in the third quarter of 2026, up 30% from the second quarter. | 99 USD million (quarter) | 2026 |
Calculated figures (shares, changes and prices per kilogram) are plain arithmetic on the reported values. Read how we work.
Companies to watch
Johnson & Johnson and Legend Biotech
Partners on the CAR-T therapy Carvykti, with about $1.9 billion of net trade sales in 2025.
Bristol Myers Squibb
Breyanzi sales were $1,358 million worldwide in 2025, up 82%.
Sarepta Therapeutics
Elevidys gene therapy net product revenue was $898.7 million in 2025.
Novartis
Zolgensma group sales were $404 million in the third quarter of 2026, up 34%.
Gilead Sciences (Kite)
Yescarta and Tecartus cell therapy sales fell 18% to $355 million in the third quarter of 2026.
Vertex Pharmaceuticals
Casgevy gene editing therapy revenue was $99 million in the third quarter of 2026.
What the full report covers
- 01Executive summary
The answer in one page: size, direction and what moves it - 02Market definition and scope
What is in and out of the global market - 03Global market size, 2021 to 2025
Historical series and growth rates - 04Countries and regions
Demand, supply and trade by country and region - 05Outlook to 2031
Base, low and high scenarios with stated assumptions - 06Rules, policy and deadlines
Regulation and programmes that change demand - 07Drivers and barriers
What accelerates or slows adoption, by customer segment - 08Prices, costs and margins
Unit economics where public data allows - 09Competitive landscape
8 to 12 company profiles with recent moves - 10Opportunities and risks
For new entrants, suppliers and investors - 11Method and assumptions
How every figure was built
Included with the full report
- PDF report, 40 to 60 pages
- Excel data pack
- Ready-to-use charts
- Method note and assumptions
- Written to order in 5 working days
Frequently asked questions
How big is the global cell and gene therapy market?
Global cell and gene therapy sales were $10.2 billion in 2025. They are forecast to reach $59.3 billion in 2031.
How many cell and gene therapies are approved worldwide?
As of the third quarter of 2026, 49 gene therapies, including genetically modified cell therapies, and 77 other cell therapies had been approved for clinical use worldwide.
What are the best-selling cell and gene therapies?
Carvykti had about $1.9 billion of net trade sales in 2025. Breyanzi sold $1,358 million and Elevidys $898.7 million in 2025.
How much investment goes into cell and gene therapy?
Cell and gene therapy companies raised more than $11.3 billion in the first three quarters of 2026, up 43% on the same period of 2025. Financing was $11.2 billion in 2025 and $15.2 billion in 2024.
How many cell and gene therapies are in development?
4,594 gene, cell and RNA therapies were in development worldwide in the third quarter of 2026, from preclinical work to pre-registration.
Which cell and gene therapy products are growing fastest?
Zolgensma group sales grew 34% to $404 million in the third quarter of 2026. Casgevy revenue rose 30% from the prior quarter to $99 million. Gilead's cell therapy sales fell 18% to $355 million.
Free sample
Get a free sample of this report
We send the table of contents, two sample chapters and the method note, usually within one working day. It is free to ask.
- Full table of contents
- Two sample chapters
- Method note and data outline